로딩 중…
지수 로딩 중…
Nurix Therapeutics, Inc.
NRIX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$25.44-0.24%
2026-09-18
Financials
Valuation Metrics
Nurix Therapeutics, Inc.'s Market Cap is $2.63B. At end of 2025 it was $2.09B. Ranked #1838 of 3,121 in US market (top 59%), #670 of 1,463 on NASDAQ (top 46%), #113 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.63B | US#1,838/3,121 Sec#113/266 |
| Revenue | $37M | US#2,793/3,121 Sec#158/266 |
| Net Income | $-341M | US—/3,121 Sec—/266 |
| Total Assets | $536M | US#2,741/3,121 Sec#156/266 |
| Net Assets | $403M | US#2,376/3,121 Sec#136/266 |
| Value | ||
| P/B | 6.53x | US#2,411/3,121 Sec#167/266 |
| P/S | 71.55x | US#2,936/3,121 Sec#171/266 |
| FCF Yield | -11.58% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -84.78% | US#2,776/3,121 Sec#196/266 |
| ROA | -63.74% | US#3,024/3,121 Sec#233/266 |
| Op. Margin | -982.37% | US#2,829/3,121 Sec#166/266 |
| Revenue Growth | -58.40% | US#2,749/3,121 Sec#165/266 |
| Financial Health | ||
| Debt Ratio | 33.01% | US#372/3,121 Sec#113/266 |
| Total Debt | $58M | US#2,584/3,121 Sec#149/266 |
| FCF | $-305M | US#2,850/3,121 Sec#233/266 |
| Cash | $68M | US#2,446/3,121 Sec#207/266 |
| Current Ratio | 6.34x | US#381/3,121 Sec#121/266 |
| Performance | ||
| 1Y Return | 183.61% | US#67/3,121 Sec#25/266 |
| 1M Return | -8.46% | US#1,766/3,121 Sec#142/266 |
| From 52W High | -9.88% | US#674/3,121 Sec#50/266 |
| 1Y MDD | -32.79% | US#1,615/3,121 Sec#107/266 |
| Trading | ||
| Volume | 2,651,285 shares | US#1,073/3,121 Sec#108/266 |
| Trading Value | $67M | US#1,463/3,121 Sec#113/266 |
| Per Share | ||
| EPS | $-3.30 | US—/3,121 Sec—/266 |
| BPS | $3.89 | US#2,376/3,121 Sec#142/266 |